Volume 82 | ESPE2014 | Next issue

ESPE 2014

Dublin, Ireland
18 Sep 2014 - 20 Sep 2014

Card image cap
Dublin, Ireland; 18-20 September 2014. Further information

Poster Category 3

Growth (3)

GH Therapy in Prepubertal Children: Results After 4 Years
aUniversity of Medicine and Pharmacy, Iasi, Romania; bRomanian Academy of Medical Sciences, Iasi, Romania
A Follow-up Study up to Adult Height of the Patients Included in the Phase iii Clinical Trial with the Biosimilar Human Recombinant GH (omnitrope®) on the Treatment of Spanish Children with GH Deficit
aHospital General Granolers, Barcelona, Spain; bHospital Universitario Carlos Haya, Malaga, Spain; cHospital Ciudad de Jaén, Jaen, Spain; dCorporación Sanitaria Parc Tauli, Barcelona, Spain; eHospital San Cecilio, Granada, Spain; fHospital Universitario Miguel Servet, Zaragoza, Spain; gHospital Sacrat Cor, Barcelona, Spain; hHospital Universitario de Salamanca, Salamanca, Spain; iHospital San Joan de Deu, Barcelona, Spain; jHospital Universitario Arnau Villanova, Lérida, Spain; kHospital Nuestra Sra Valme, Sevilla, Spain; lSandoz Farmacéutica, Madrid, Spain
Growth pattern of the nigerian child compared to international references
aDepartment of Paediatrics and Child Health, Obafemi Awolowo University, Ile-Ife, Nigeria; bDepartment of Paediatrics, Federal Teaching Hospital, Abakaliki, Ebonyi State, Nigeria; cDepartment of Paediatrics, Federal Medical Centre, Gombe, Gombe, Nigeria; dDepartment of Paediatrics, Sandwell and West Birmingham NHS Trust, West Bromwich, UK
Evaluation of Potential Waste of GH Across Available GH Pen Devices and an Electronic GH Delivery Device
aEMD Serono, Inc., Rockland, Massachusetts, USA; bHealth Services Consulting Corporation, Boxborough, Massachusetts, USA
Switching From the Original to the Biosimilar Recombinant Human GH - Omnitrope[reg]: an Experience of a Single Paediatric Centre in Spain
aHospital Universitario Virgen del Rocío, Sevilla, Spain; bSandoz Farmacéutica, Madrid, Spain
Descriptive Analysis of Medication Adherence for Patients Treated with GH Therapy
aCompetitive Health Analytics – A Humana Company, Louisville, Kentucky, USA; bEMD Serono, Inc., Rockland, Massachusetts, USA; cFormerly EMD Serono, Inc., Rockland, Massachusetts, USA
Effect of Cyanotic and Acyanotic Congenital Heart Disease on Placental and Birth Size
aDepartment of Pediatrics Hamad Medical Center, Doha, Qatar; bNeonatal ICU Hamad Medical Center, Doha, Qatar
Differences in Personality of Monozygotic Twins can be Predicted by Difference in Birth Weight in Teen Monozygotic Twins
aPediatric Endocrinology Division, Children’s Hospital, University of Bonn, Bonn, Germany; bDepartment of Neonatology, Children’s Hospital, University of Bonn, Bonn, Germany
The Growth Speed of Late Pretem Infants Aged 1 Year
Department of Primary Child Health Care, Children’s Hospital, Chongqing Medical University, Chongqing, China
Response of GH Therapy in Six Children with Achondroplasia
aDepartment of Pediatrics, Keimyung University School of Medicine, Daegu, Republic of Korea; bDepartment of Radiology, Keimyung University School of Medicine, Daegu, Republic of Korea
Clinical Expression of Familial Williams-Beuren Syndrome in a Turkish Family
aDepartment of Pediatric Endocrinology, Akdeniz University School of Medicine, Antalya, Turkey; bDepartment of Pediatric Genetics, Akdeniz University School of Medicine, Antalya, Turkey; cDepartment of Medical Biology and Genetics, Akdeniz University School of Medicine, Antalya, Turkey
Abstract unavailable